C. Kensil

发表

Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy.

W. Fairbrother, N. Jacobsen, C. Kensil, 1996, Carbohydrate research.

Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex.

C. Kensil, M. Lennick, U. Patel, 1991, Journal of immunology.

Structural and immunological characterization of the vaccine adjuvant QS-21.

C. Kensil, J. Y. Wu, S. Soltysik, 1995, Pharmaceutical biotechnology.

Effects of QS-21 on Innate and Adaptive Immune Responses

C. Kensil, J. Storey, Gui Liu, 2006 .

Immunomodulatory adjuvants from Quillaja saponaria

C. Kensil, 2006 .

QS-21 structure/function studies: effect of acylation on adjuvant activity.

C. Kensil, Gui Liu, C. Anderson, 2002, Vaccine.

A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.

C. Kensil, G. Corradin, J. Romero, 2005, Vaccine.

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

C. Kensil, Philip S. Livingston, D. Marciani, 1994, Vaccine.

Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

C. Kensil, J. Y. Wu, M. Newman, 1992, Journal of immunology.

Saponins as vaccine adjuvants.

C. Kensil, 1996, Critical reviews in therapeutic drug carrier systems.

Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

C. Kensil, J. Y. Wu, M. Newman, 1992, Journal of immunology.

Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes

H. Mohri, N. Ishii, J. Fukushima, 1998, Journal of Virology.

Current vaccine adjuvants: an overview of a diverse class.

C. Kensil, A. Truneh, Annie X. Y. Mo, 2004, Frontiers in bioscience : a journal and virtual library.

DS-1, a modified Quillaja saponin, enhances ocular and nasal absorption of insulin.

C. Kensil, D. Marciani, D. Pillion, 1995, Journal of pharmaceutical sciences.

Structure-function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin.

C. Kensil, D. Pillion, J. Recchia, 1996, Journal of pharmaceutical sciences.

Oral QS-21 Requires Early IL-4 Help for Induction of Mucosal and Systemic Immunity1

M. Marinaro, J. Mcghee, K. Kirk, 2001, The Journal of Immunology.

ImmunityInduction of Mucosal and Systemic Oral QS-21 Requires Early IL-4 Help for

M. Marinaro, J. Mcghee, K. Kirk, 2001 .

Epidermal powder immunization of mice and monkeys with an influenza vaccine.

Y. Maa, Dexiang Chen, C. Kensil, 2003, Vaccine.

QS-21: a water-soluble triterpene glycoside adjuvant.

C. Kensil, Kensil Cr, R. Kammer, 1998, Expert opinion on investigational drugs.

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function.

C. Kensil, D. A. Wheeler, J. Y. Wu, 1995, Vaccine.

Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi.

C. Pavia, C. Kensil, D. Davis, 1994, Vaccine.

Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes.

C. Kensil, J. Y. Wu, M. Newman, 1994, Cellular Immunology.

Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats.

C. Kensil, D. Marciani, A. Aubert, 1991, Vaccine.

Action of cobra venom phospholipase A2 on large unilamellar vesicles: Comparison with small unilamellar vesicles and multibilayers

E. Dennis, C. Kensil, 1985, Lipids.

Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria.

C. Kensil, D. A. Wheeler, J. Y. Wu, 1996, Advances in experimental medicine and biology.

Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.

T. Wrin, J. Vennari, C. Kensil, 1995, AIDS research and human retroviruses.

Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant.

C. Kensil, J. Y. Wu, M. Newman, 1994, AIDS research and human retroviruses.

Development of a genetically engineered vaccine against feline leukemia virus infection.

C. Kensil, U. Patel, D. Marciani, 1991, Journal of the American Veterinary Medical Association.

Binding and fluorescence properties of the membrane domain of NADH-cytochrome-b5 reductase. Determination of the depth of Trp-16 in the bilayer.

P. Strittmatter, C. Kensil, 1986, The Journal of biological chemistry.

Cobra venom phospholipase A2: A review of its action toward lipid/water interfaces

A. Plückthun, E. Dennis, P. Darke, 1981, Molecular and Cellular Biochemistry.

Alkaline hydrolysis of phospholipids in model membranes and the dependence on their state of aggregation.

E. Dennis, C. Kensil, 1981, Biochemistry.

A Semisynthetic Quillaja Saponin as a Drug Delivery Agent for Aminoglycoside Antibiotics

C. Kensil, J. Storey, J. Recchia, 1995, Pharmaceutical Research.

Genetic analysis of Escherichia coli mutants defective in adenylate kinase and sn-glycerol 3-phosphate acyltransferase

C. Kensil, M. Glaser, B. Esmon, 1980, Journal of bacteriology.

Enhancement of intestinal model compound transport by DS-1, a modified Quillaja saponin.

P. Daddona, A. Chao, C. Kensil, 1998, Journal of pharmaceutical sciences.

Action of cobra venom phospholipase A2 on the gel and liquid crystalline states of dimyristoyl and dipalmitoyl phosphatidylcholine vesicles.

E. Dennis, C. Kensil, 1979, The Journal of biological chemistry.

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

F. Ennis, R. Edelman, C. Kensil, 2001, Vaccine.

QS-21 and QS-7: purified saponin adjuvants.

C. Kensil, D. A. Wheeler, J. Y. Wu, 1998, Developments in biological standardization.

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.

T. Wrin, A. Daugherty, J. Vennari, 1996, Journal of pharmaceutical sciences.

Isomerization and formulation stability of the vaccine adjuvant QS-21.

N. Jacobsen, C. Kensil, A. Lim, 1996, Journal of pharmaceutical sciences.

Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection.

C. Kensil, N. Kushner, C. Barrett, 1991, Journal of the American Veterinary Medical Association.

Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.

C. Kensil, M. Powell, J. Y. Wu, 1997, Vaccine.

Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice.

C. Kensil, A. Lal, C. Hackett, 2002, Experimental parasitology.

QS-21 Adjuvant

C. Kensil, 2000 .

Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.

W. Britt, C. Kensil, J. Fay, 1995, The Journal of infectious diseases.

Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates.

C. Kensil, J. Y. Wu, M. Newman, 1992, AIDS research and human retroviruses.

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

C. Kensil, S. Soltysik, D. Bedore, 2001 .

Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.

D. Kaslow, V. Price, C. Kensil, 2001, Experimental parasitology.

Saponines purifiees servant d'adjuvants oraux

M. Marinaro, J. Mcghee, C. Kensil, 1998 .

Adjuvant Activity of QS‐21 Isomers

C. Kensil, S. Soltysik, D. Bedore, 1993, Annals of the New York Academy of Sciences.

QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum

A. Goldstein, C. Kensil, D. Marciani, 1992 .